Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT
Journal Title: Annals of Hepatology - Year 2012, Vol 11, Issue 2
Abstract
Background. Approximately one-third of patients with chronic hepatitis C virus infection have persistently normal liver enzymes reflected by a normal serum alanine transaminase (ALT). Data with regards the efficacy and safety of treatment in patients chronically infected with Hepatitis C virus genotype 4 and normal serum ALT are limited. Aim. To evaluate the efficacy and safety of peginterferon alfa-2b plus ribavirin combination therapy in this population. Material and methods. Twenty-two patients with chronic hepatitis C virus genotype 4 infection were enrolled in an open-labeled, uncontrolled pilot study. All patients had biopsy proven chronic hepatitis and persistently normal serum ALT levels. Patients were treated with subcutaneous peginterferon alfa-2b at a dose of 1.5 µg/kg body weight once per week plus oral ribavirin (15 mg/kg/day) for 48 weeks. Patients were followed for 24 weeks post-treatment. Results. Sixteen patients out of twenty two completed the study (9 [40.9%] females, mean age 43.8 years). The ALT level were normal in all patients, with a mean of 38.6 U/L. Sustained viral response was achieved in 13 patients (59%), 4 patients (18.1%) were non-responders and 2 patients (9%) relapsed while 1 patient had a viral breakthrough during treatment. Two patients (9%) discontinued the treatment because of adverse events. Conclusions.Combination therapy of pegylated interferon-alpha2b and ribavirin is safe and resulted in a sustained virological response in a significant number of patients with chronic Hepatitis C, genotype 4, and persistently normal serum ALT.
Authors and Affiliations
Jaber Al-Ali, Iqbal Siddique, Rosh Varghese, Fuad Hasan
Keywords
Related Articles
- EP ID EP78121
- DOI -
- Views 113
- Downloads 0
Serum homocysteine levels in patients with nonalcoholic fatty liver disease
Background and rational for the study. Nonalcoholic fatty liver disease (NAFLD) is regarded as the hepatic component of insulin resistance (IR) syndrome, but data on serum homocysteine (HCY) are limited. The aim of the s...
Therapeutic Effect of HGF on NASH Mice Through HGF/c-Met and JAK2-STAT3 Signalling Pathway
Introduction and aim. Hepatocyte growth factor (HGF) has been shown to ameliorate liver inflammation and fibrosis; however, the mechanism underlying its effects in non-alcoholic steatohepatitis (NASH) is unclear. This st...
Hepatitis E virus serum antibodies and RNA prevalence in patients evaluated for heart and kidney transplantation
Background. Acute hepatitis E virus (HEV) infection in solid organ transplant recipients is rare, but cancause severe hepatic and extrahepatic complications. We sought to identify the pretransplant prevalenceof HEV infec...
Molecular surveillance of hepatitis A virus in Argentina: first subgenotype IB detected in a traveler
By using molecular surveillance of hepatitis A virus, we characterized for the first time a subgenotype IB imported case in Argentina, a country with universal vaccination since 2005. The case was a crew member of a crui...
Portopulmonary hypertension: state of the art
Portopulmonary hypertension is an uncommon but treatable pulmonary vascular consequence of portal hypertension, which can lead to significant morbidity and mortality. Portopulmonary hypertension results from excessive pu...